Gerhard Rogler

List of Publications by Citations

Source: https://exaly.com/author-pdf/3225626/gerhard-rogler-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

523 papers	21,772 citations	72 h-index	123 g-index
627 ext. papers	26,063 ext. citations	5.3 avg, IF	6.91 L-index

#	Paper	IF	Citations
523	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. *Journal of Crohn's and Colitis*, **2010**, 4, 7-27	1.5	808
522	Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. *Journal of Clinical Investigation*, **1996**, 97, 1715-22	15.9	626
521	Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. *Gastroenterology*, **1998**, 115, 357-69	13.3	592
520	Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. *Journal of Crohn's and Colitis*, **2013**, 7, 556-85	1.5	438
519	Cytokines in inflammatory bowel disease. *World Journal of Surgery*, **1998**, 22, 382-9	3.3	417
518	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. *Journal of Crohn's and Colitis*, **2017**, 11, 135-149	1.5	387
517	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. *Journal of Crohn's and Colitis*, **2013**, 7, 1-33	1.5	361
516	Extraintestinal Manifestations of Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2015**, 21, 1982-92	4.5	316
515	Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. *PLoS ONE*, **2007**, 2, e1308	3.7	297
514	Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. *American Journal of Gastroenterology*, **2011**, 106, 110-9	0.7	291
513	Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders. *Frontiers in Psychiatry*, **2018**, 9, 44	5	276
512	Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. *PLoS ONE*, **2013**, 8, e59260	3.7	245
511	Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. *Blood*, **2004**, 104, 889-94	2.2	239
510	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. *Journal of Crohn's and Colitis*, **2015**, 9, 945-65	1.5	229
509	Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. *Gastroenterology*, **2007**, 132, 190-207	13.3	224
508	Wound healing and fibrosis in intestinal disease. *Gut*, **2007**, 56, 130-9	19.2	208
507	Memory B Cells Activate Brain-Homing, Autoreactive CD4 T Cells in Multiple Sclerosis. *Cell*, **2018**, 175, 85-100.e23	56.2	207

506	Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. *Gastroenterology*, **2017**, 152, 340-350.e6	13.3	190
505	Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 829-835.e1	6.9	184
504	Chronic ulcerative colitis and colorectal cancer. *Cancer Letters*, **2014**, 345, 235-41	9.9	184
503	Use of self-expandable plastic stents for the treatment of esophageal perforations and symptomatic anastomotic leaks. *Endoscopy*, **2004**, 36, 695-9	3.4	172
502	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. *American Journal of Hematology*, **2017**, 92, 1068-1078	7.1	168
501	Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 71-83	6.1	167
500	Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. *Blood*, **2006**, 107, 4189-93	2.2	156
499	Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2012**, 18, 496-505	4.5	147
498	Abdominal MRI after enteroclysis or with oral contrast in patients with suspected or proven CrohnÞ disease. *Clinical Gastroenterology and Hepatology*, **2004**, 2, 491-7	6.9	147
497	Isolation and phenotypic characterization of colonic macrophages. *Clinical and Experimental Immunology*, **1998**, 112, 205-15	6.2	146
496	Microbial network disturbances in relapsing refractory CrohnÞ disease. *Nature Medicine*, **2019**, 25, 323-336	36.5	144
495	Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected small bowel disease. *International Journal of Colorectal Disease*, **2006**, 21, 97-104	3	140
494	Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. *Gut*, **2017**, 66, 1216-1224	19.2	137
493	Diagnostic delay in CrohnÞ disease is associated with a complicated disease course and increased operation rate. *American Journal of Gastroenterology*, **2013**, 108, 1744-53; quiz 1754	0.7	128
492	Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. *Nature Communications*, **2017**, 8, 98	17.4	125
491	NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. *Journal of Clinical Investigation*, **2016**, 126, 1783-800	15.9	125
490	In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis. *Clinical and Experimental Immunology*, **2007**, 148, 373-81	6.2	123
489	Growth of Epithelial Organoids in a Defined Hydrogel. *Advanced Materials*, **2018**, 30, e1801621	24	114

488	Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. *Journal of Crohn's and Colitis*, **2014**, 8, 1147-65	1.5	109
487	Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. *Inflammatory Bowel Diseases*, **2010**, 16, 630-7	4.5	108
486	Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. *Inflammatory Bowel Diseases*, **2015**, 21, 1794-800	4.5	107
485	Cell-cell contacts prevent anoikis in primary human colonic epithelial cells. *Gastroenterology*, **2007**, 132, 587-600	13.3	106
484	Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH. *Inflammatory Bowel Diseases*, **2014**, 20, 1496-501	4.5	105
483	Analysis of intestinal haem-oxygenase-1 (HO-1) in clinical and experimental colitis. *Clinical and Experimental Immunology*, **2005**, 140, 547-55	6.2	104
482	The intestinal microbiota: its role in health and disease. *European Journal of Pediatrics*, **2015**, 174, 151-67	4.1	102
481	Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2015**, 314, 2524-34	27.4	102
480	Profiling adipocytokine secretion from creeping fat in Crohn's disease. *Inflammatory Bowel Diseases* , **2006**, 12, 471-7	4.5	102
479	Gastrointestinal and liver adverse effects of drugs used for treating IBD. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2010**, 24, 157-65	2.5	101
478	Comparison of magnetic resonance imaging colonography with conventional colonoscopy for the assessment of intestinal inflammation in patients with inflammatory bowel disease: a feasibility study. *Gut*, **2005**, 54, 250-6	19.2	98
477	HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 683-90	9.4	96
476	Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. *Inflammatory Bowel Diseases*, **2008**, 14, 1514-27	4.5	93
475	Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. *Journal of Proteome Research*, **2007**, 6, 1114-25	5.6	90
474	Sexual function in persons with inflammatory bowel disease: a survey with matched controls. *Clinical Gastroenterology and Hepatology*, **2007**, 5, 87-94	6.9	87
473	Morphological characterisation of Crohn's disease fistulae. *Gut*, **2004**, 53, 1314-21	19.2	87
472	Interleukin-13 and transforming growth factor 1 synergise in the pathogenesis of human intestinal fistulae. *Gut*, **2013**, 62, 63-72	19.2	85
471	Diagnosis and management of fistulizing Crohn's disease. *Nature Reviews Gastroenterology & Hepatology*, **2009**, 6, 92-106		85

470	CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. *Gastroenterology*, **2005**, 129, 913-27	13.3	85
469	The heart and the gut. *European Heart Journal*, **2014**, 35, 426-30	9.5	83
468	Identification of a SIRT1 mutation in a family with type 1 diabetes. *Cell Metabolism*, **2013**, 17, 448-455	24.6	83
467	Protection of epithelial barrier function by the Crohn‚ disease associated gene protein tyrosine phosphatase n2. *Gastroenterology*, **2009**, 137, 2030-2040.e5	13.3	83
466	13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells. *Biochemical Pharmacology*, **2007**, 74, 612-22	6	83
465	Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn‚ disease. *American Journal of Gastroenterology*, **2002**, 97, 2688-90	0.7	83
464	Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo. *Clinical and Experimental Immunology*, **2006**, 146, 169-80	6.2	82
463	Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. *Gastroenterology*, **2003**, 125, 1341-54	13.3	79
462	Autophagy gene Atg16L1 prevents lethal T cell alloreactivity mediated by dendritic cells. *Immunity*, **2014**, 41, 579-91	32.3	75
461	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn‚ disease (ANDANTE I and II). *Gut*, **2019**, 68, 40-48	19.2	75
460	Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot study. *Journal of Crohn‚s and Colitis*, **2013**, 7, 271-9	1.5	74
459	Hallmarks of epithelial to mesenchymal transition are detectable in Crohn‚ disease associated intestinal fibrosis. *Clinical and Translational Medicine*, **2015**, 4, 1	5.7	73
458	Development of an index to define overall disease severity in IBD. *Gut*, **2018**, 67, 244-254	19.2	73
457	Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn‚ disease behavior. *Inflammatory Bowel Diseases*, **2010**, 16, 263-74	4.5	73
456	Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. *Gut*, **2000**, 46, 350-8	19.2	73
455	Milk oligosaccharide sialyl(‚,3)lactose activates intestinal CD11c+ cells through TLR4. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 17444-9	11.5	72
454	The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. *European Journal of Gastroenterology and Hepatology*, **2008**, 20, 917-23	2.2	72
453	Dark lumen magnetic resonance enteroclysis in combination with MRI colonography for whole bowel assessment in patients with Crohn‚ disease: first clinical experience. *Inflammatory Bowel Diseases*, **2005**, 11, 388-94	4.5	72

452	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1381-1392	6.9	71
451	Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease. *Journal of Crohn's and Colitis*, **2016**, 10, 377-86	1.5	69
450	Transforming growth factor-beta 1 induces intestinal myofibroblast differentiation and modulates their migration. *World Journal of Gastroenterology*, **2009**, 15, 1431-42	5.6	69
449	Modern imaging using computer tomography and magnetic resonance imaging for inflammatory bowel disease (IBD) AU1. *Inflammatory Bowel Diseases*, **2004**, 10, 45-54	4.5	69
448	Exposome in IBD: recent insights in environmental factors that influence the onset and course of IBD. *Inflammatory Bowel Diseases*, **2015**, 21, 400-8	4.5	68
447	Cellular and Molecular Mediators of Intestinal Fibrosis. *Journal of Crohn's and Colitis*, **2017**, 11, 1491-1503	1.5	68
446	Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 977-89	6.1	67
445	Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. *Inflammatory Bowel Diseases*, **2010**, 16, 1367-75	4.5	67
444	Regulation of migration of human colonic myofibroblasts. *Growth Factors*, **2002**, 20, 81-91	1.6	67
443	Magnetization transfer for the assessment of bowel fibrosis in patients with Crohn's disease: initial experience. *Magnetic Resonance Materials in Physics, Biology, and Medicine*, **2013**, 26, 291-301	2.8	66
442	Nuclear factor-kappa B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. *Clinical and Experimental Immunology*, **2000**, 120, 59-65	6.2	66
441	Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account. *PLoS ONE*, **2016**, 11, e0156666	3.7	66
440	Inflammatory bowel disease pathogenesis: what is new?. *Current Opinion in Gastroenterology*, **2012**, 28, 301-9	3	64
439	Pathophysiology of fistula formation in Crohn's disease. *World Journal of Gastrointestinal Pathophysiology*, **2014**, 5, 205-12	3.2	64
438	Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. *Mucosal Immunology*, **2014**, 7, 589-601	9.2	63
437	Alterations of the phenotype of colonic macrophages in inflammatory bowel disease. *European Journal of Gastroenterology and Hepatology*, **1997**, 9, 893-9	2.2	63
436	Periodontitis and gingivitis in inflammatory bowel disease: a case-control study. *Inflammatory Bowel Diseases*, **2013**, 19, 2768-77	4.5	62
435	PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner. *Autophagy*, **2017**, 13, 1590-1601	10.2	61

434	Update in inflammatory bowel disease pathogenesis. *Current Opinion in Gastroenterology*, **2004**, 20, 311-7	3	61
433	PTPN2 controls differentiation of CD4+ T cells and limits intestinal inflammation and intestinal dysbiosis. *Mucosal Immunology*, **2015**, 8, 918-29	9.2	60
432	Inflammatory bowel disease: dysfunction of autophagy?. *Digestive Diseases*, **2012**, 30 Suppl 3, 12-9	3.2	59
431	Differential activation of cytokine secretion in primary human colonic fibroblast/myofibroblast cultures. *Scandinavian Journal of Gastroenterology*, **2001**, 36, 389-98	2.4	58
430	Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin. *Neurogastroenterology and Motility*, **2013**, 25, 467-73	4	57
429	Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. *Inflammatory Bowel Diseases*, **2007**, 13, 727-32	4.5	56
428	Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment. *Journal of Pediatric Gastroenterology and Nutrition*, **2017**, 65, 200-206	2.8	55
427	Sphingomyelin induces cathepsin D-mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis. *Gut*, **2011**, 60, 55-65	19.2	55
426	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. *Gastroenterology*, **2020**, 159, 139-147	13.3	54
425	Protein tyrosine phosphatase N2 regulates TNF-induced signalling and cytokine secretion in human intestinal epithelial cells. *Gut*, **2011**, 60, 189-97	19.2	54
424	Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. *Intensive Care Medicine*, **2007**, 33, 1541-8	14.5	54
423	Soluble galectin-3 is a strong, colonic epithelial-cell-derived, lamina propria fibroblast-stimulating factor. *Gut*, **2007**, 56, 43-51	19.2	54
422	Genome-Scale CRISPR Screening in Human Intestinal Organoids Identifies Drivers of TGF- Resistance. *Cell Stem Cell*, **2020**, 26, 431-440.e8	18	53
421	Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. *Inflammatory Bowel Diseases*, **2012**, 18, 900-12	4.5	53
420	Determinants of male sexual function in inflammatory bowel disease: a survey-based cross-sectional analysis in 280 men. *Inflammatory Bowel Diseases*, **2007**, 13, 1236-43	4.5	53
419	Helicobacter pylori-specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18. *Inflammatory Bowel Diseases*, **2015**, 21, 854-61	4.5	52
418	PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer. *Cell Reports*, **2018**, 22, 1835-1848	10.6	52
417	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 399-406	18.8	52

416	Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. *Gut*, **2014**, 63, 272-80	19.2	51
415	Epidermal growth factor partially restores colonic ion transport responses in mouse models of chronic colitis. *Gastroenterology*, **2005**, 129, 591-608	13.3	51
414	The Trp64Arg Polymorphism of the β3-Adrenergic Receptor Gene Is Not Associated with Obesity or Type 2 Diabetes Mellitus in a Large Population-Based Caucasian Cohort. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 2892-2897	5.6	51
413	Functional characterisation of decoy receptor 3 in Crohn's disease. *Gut*, **2009**, 58, 483-91	19.2	50
412	Orofacial granulomatosis as the initial presentation of Crohn's disease in an adolescent. *Dermatology*, **2003**, 206, 273-8	4.4	50
411	Succinate receptor mediates intestinal inflammation and fibrosis. *Mucosal Immunology*, **2019**, 12, 178-187	7.2	50
410	Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. *Journal of Crohn's and Colitis*, **2018**, 12, 811-818	1.5	49
409	Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. *World Journal of Gastroenterology*, **2009**, 15, 3134-41	5.6	49
408	Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells. *Gastroenterology*, **2011**, 140, 2019-30	13.3	48
407	Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 67-74	4.7	48
406	Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts. *Gut*, **2003**, 52, 1448-56	19.2	48
405	Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. *PLoS ONE*, **2016**, 11, e0154817	3.7	48
404	Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells. *Journal of Biological Chemistry*, **2004**, 279, 10304-15	5.4	47
403	Mucosal healing and deep remission: what does it mean?. *World Journal of Gastroenterology*, **2013**, 19, 7552-60	5.6	47
402	Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. *Inflammatory Bowel Diseases*, **2017**, 23, 1174-1181	4.5	46
401	G Protein-coupled pH-sensing Receptor OGR1 Is a Regulator of Intestinal Inflammation. *Inflammatory Bowel Diseases*, **2015**, 21, 1269-81	4.5	46
400	European society of neurogastroenterology and motility guidelines on functional constipation in adults. *Neurogastroenterology and Motility*, **2020**, 32, e13762	4	46
399	Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease Complications with Fibrosis. *Inflammatory Bowel Diseases*, **2016**, 22, 2041-57	4.5	45

398	Bilberries and their anthocyanins ameliorate experimental colitis. *Molecular Nutrition and Food Research*, **2011**, 55, 1724-9	5.9	45
397	Clinical relevance of IgG antibodies against food antigens in Crohn's disease: a double-blind cross-over diet intervention study. *Digestion*, **2010**, 81, 252-64	3.6	45
396	Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. *Inflammatory Bowel Diseases*, **2003**, 9, 302-7	4.5	45
395	Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages. *Clinical and Experimental Immunology*, **2001**, 125, 48-55	6.2	45
394	Irritable bowel syndrome among a cohort of European travelers to resource-limited destinations. *Journal of Travel Medicine*, **2011**, 18, 250-6	12.9	44
393	Epidermal Growth Factor Partially Restores Colonic Ion Transport Responses in Mouse Models of Chronic Colitis. *Gastroenterology*, **2005**, 129, 591-608	13.3	44
392	Topical therapy is underused in patients with ulcerative colitis. *Journal of Crohn's and Colitis*, **2014**, 8, 56-63	1.5	43
391	Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells. *Inflammatory Bowel Diseases*, **2012**, 18, 1287-302	4.5	43
390	Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. *Journal of Crohn's and Colitis*, **2010**, 4, 642-8	1.5	43
389	Burrowing is a sensitive behavioural assay for monitoring general wellbeing during dextran sulfate sodium colitis in laboratory mice. *Laboratory Animals*, **2013**, 47, 274-83	2.6	42
388	Glucocorticoid receptors are down-regulated in inflamed colonic mucosa but not in peripheral blood mononuclear cells from patients with inflammatory bowel disease. *European Journal of Clinical Investigation*, **1999**, 29, 330-6	4.6	42
387	T-cell co-stimulatory molecules are upregulated on intestinal macrophages from inflammatory bowel disease mucosa. *European Journal of Gastroenterology and Hepatology*, **1999**, 11, 1105-11	2.2	42
386	Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). *Inflammatory Bowel Diseases*, **2012**, 18, 1523-30	4.5	41
385	Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes. *Clinical and Experimental Immunology*, **2006**, 145, 190-9	6.2	41
384	Autocrine fibronectin-induced migration of human colonic fibroblasts. *American Journal of Gastroenterology*, **2004**, 99, 335-40	0.7	41
383	Cathepsin D is up-regulated in inflammatory bowel disease macrophages. *Clinical and Experimental Immunology*, **2004**, 136, 157-67	6.2	41
382	Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs. *Journal of Crohn's and Colitis*, **2016**, 10, 758-65	1.5	40
381	Loss of protein tyrosine phosphatase nonreceptor type 22 regulates interferon-γ-induced signaling in human monocytes. *Gastroenterology*, **2013**, 144, 978-988.e10	13.3	40

380	Progress on isolation and short-term ex-vivo culture of highly purified non-apoptotic human intestinal epithelial cells (IEC). *European Journal of Cell Biology*, **2003**, 82, 262-70	6.1	40
379	Association of antibodies to exocrine pancreas with subtypes of Crohn‚ disease. *European Journal of Gastroenterology and Hepatology*, **2005**, 17, 73-7	2.2	40
378	Crohn‚ disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. *European Journal of Gastroenterology and Hepatology*, **2005**, 17, 395-401	2.2	40
377	Growth and cell cycle abnormalities of fibroblasts from Tangier disease patients. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 28-38	9.4	39
376	Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. *Gastroenterology*, **2019**, 156, 946-957.e18	13.3	39
375	Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. *United European Gastroenterology Journal*, **2016**, 4, 97-104	5.3	38
374	Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. *BMC Research Notes*, **2012**, 5, 461	2.3	38
373	Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing. *Journal of Crohn‚s and Colitis*, **2012**, 6, 373-85	1.5	38
372	Top-down or step-up treatment in Crohn‚ disease?. *Digestive Diseases*, **2013**, 31, 83-90	3.2	38
371	Intracellular polyamine levels of intestinal epithelial cells in inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2004**, 10, 529-35	4.5	38
370	High Rates of Smoking Especially in Female Crohn‚ Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation--Data from the Swiss IBD Cohort Study. *Journal of Crohn‚s and Colitis*, **2015**, 9, 819-29	1.5	37
369	First-line therapies in inflammatory bowel disease. *Digestion*, **2012**, 86 Suppl 1, 6-10	3.6	37
368	Potential role for SNAIL family transcription factors in the etiology of Crohn‚ disease-associated fistulae. *Inflammatory Bowel Diseases*, **2011**, 17, 1907-16	4.5	37
367	Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. *BMC Cancer*, **2010**, 10, 302	4.8	37
366	Inhibition of proteasome activity by anthocyanins and anthocyanidins. *Biochemical and Biophysical Research Communications*, **2008**, 372, 57-61	3.4	37
365	Long-term changes of bacterial and viral compositions in the intestine of a recovered Clostridium difficile patient after fecal microbiota transplantation. *Journal of Physical Education and Sports Management*, **2016**, 2, a000448	2.8	37
364	Anthocyanins Prevent Colorectal Cancer Development in a Mouse Model. *Digestion*, **2017**, 95, 275-280	3.6	36
363	Mutant HRAS as novel target for MEK and mTOR inhibitors. *Oncotarget*, **2015**, 6, 42183-96	3.3	36

362	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. *Lancet, The*, **2021**, 397, 2372-2384	40	36
361	A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease. *Journal of Crohn's and Colitis*, **2017**, 11, 390-399	1.5	36
360	White-Light or Narrow-Band Imaging Colonoscopy in Surveillance of Ulcerative Colitis: A Prospective Multicenter Study. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1776-1781.e1	6.9	35
359	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. *Inflammatory Intestinal Diseases*, **2019**, 4, 79-96	2.5	35
358	BCL-2 modifying factor (BMF) is a central regulator of anoikis in human intestinal epithelial cells. *Journal of Biological Chemistry*, **2011**, 286, 26533-40	5.4	35
357	A role for interleukin-33 in T(H)2-polarized intestinal inflammation?. *Mucosal Immunology*, **2011**, 4, 496-502	9.2	35
356	IL-15 protects intestinal epithelial cells. *European Journal of Immunology*, **2006**, 36, 2691-9	6.1	35
355	Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease. *United European Gastroenterology Journal*, **2019**, 7, 767-781	5.3	34
354	The Proton-activated Receptor GPR4 Modulates Intestinal Inflammation. *Journal of Crohn's and Colitis*, **2018**, 12, 355-368	1.5	34
353	Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists. *Endoscopy*, **2016**, 48, 256-62	3.4	34
352	Ephrin-B2 is differentially expressed in the intestinal epithelium in Crohn's disease and contributes to accelerated epithelial wound healing in vitro. *World Journal of Gastroenterology*, **2005**, 11, 4024-31	5.6	33
351	Resolution of inflammation in inflammatory bowel disease. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 521-530	18.8	32
350	Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. *Kidney International*, **2019**, 96, 890-905	9.9	32
349	CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. *Clinical and Experimental Immunology*, **2009**, 155, 534-40	6.2	32
348	Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. *Inflammatory Bowel Diseases*, **2010**, 16, 1311-21	4.5	32
347	Bile salt-induced apoptosis in human colon cancer cell lines involves the mitochondrial transmembrane potential but not the CD95 (Fas/Apo-1) receptor. *International Journal of Colorectal Disease*, **2005**, 20, 103-13	3	32
346	Protein tyrosine phosphatase non-receptor type 22 modulates NOD2-induced cytokine release and autophagy. *PLoS ONE*, **2013**, 8, e72384	3.7	32
345	Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. *PLoS ONE*, **2017**, 12, e0185193	3.7	32

344	CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac disease. *American Journal of Gastroenterology*, **2013**, 108, 1344-51	0.7	31
343	Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations. *European Journal of Clinical Pharmacology*, **2013**, 69, 1521-31	2.8	31
342	Partial replacement of dietary (n-6) fatty acids with medium-chain triglycerides decreases the incidence of spontaneous colitis in interleukin-10-deficient mice. *Journal of Nutrition*, **2009**, 139, 603-10	4.1	31
341	Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. *Alimentary Pharmacology and Therapeutics*, **2003**, 17, 409-14	6.1	31
340	Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. *PLoS ONE*, **2012**, 7, e43361	3.7	31
339	High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients. *Journal of Crohn's and Colitis*, **2014**, 8, 191-9	1.5	30
338	Recent advances using immunomodulators for inflammatory bowel disease. *Journal of Clinical Pharmacology*, **2013**, 53, 575-88	2.9	30
337	Analysis of the intestinal microbiome of a recovered Clostridium difficile patient after fecal transplantation. *Digestion*, **2013**, 88, 243-51	3.6	30
336	Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation. *Clinical and Experimental Immunology*, **2008**, 152, 285-97	6.2	30
335	Do we need gastric acid?. *Digestion*, **2008**, 77, 184-97	3.6	30
334	Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture. *FASEB Journal*, **2003**, 17, 1115-7	0.9	30
333	Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis. *Inflammatory Bowel Diseases*, **2016**, 22, 569-82	4.5	30
332	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. *Gastroenterology*, **2018**, 155, 76-87	13.3	29
331	Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. *Journal of Crohn's and Colitis*, **2013**, 7, 670-7	1.5	29
330	Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists. *Journal of Clinical Pathology*, **2014**, 67, 582-6	3.9	29
329	Inflammatory bowel disease cancer risk, detection and surveillance. *Digestive Diseases*, **2012**, 30 Suppl 2, 48-54	3.2	29
328	Inverse regulation of the ADAM-family members, decysin and MADDAM/ADAM19 during monocyte differentiation. *Immunology*, **2003**, 110, 450-7	7.8	29
327	Where are we heading to in pharmacological IBD therapy?. *Pharmacological Research*, **2015**, 100, 220-7	10.2	28

326	Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. *Scandinavian Journal of Gastroenterology*, **2016**, 51, 848-54	2.4	28
325	Biologics for extraintestinal manifestations of IBD. *Current Drug Targets*, **2014**, 15, 1064-73	3	28
324	Probiotic Escherichia coli Nissle 1917 and commensal E. coli K12 differentially affect the inflammasome in intestinal epithelial cells. *Digestion*, **2014**, 89, 110-8	3.6	28
323	Risk factors for repetitive ileocolic resection in patients with Crohn‚ disease: results of an observational cohort study. *Inflammatory Bowel Diseases*, **2014**, 20, 1548-54	4.5	28
322	Polymorphism of monocyte chemoattractant protein 1 in Crohn‚ disease. *International Journal of Colorectal Disease*, **2003**, 18, 401-5	3	28
321	Characterization of changes in serum anti-glycan antibodies in Crohn‚ disease--a longitudinal analysis. *PLoS ONE*, **2011**, 6, e18172	3.7	28
320	The Search for Causative Environmental Factors in Inflammatory Bowel Disease. *Digestive Diseases*, **2016**, 34 Suppl 1, 48-55	3.2	28
319	Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn‚ Disease. *American Journal of Gastroenterology*, **2016**, 111, 529-40	0.7	27
318	Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohn‚ disease. *European Journal of Gastroenterology and Hepatology*, **2014**, 26, 114-8	2.2	27
317	Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. *World Journal of Gastroenterology*, **2007**, 13, 5217-25	5.6	27
316	The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years. *Journal of Crohn‚s and Colitis*, **2019**, 13, 744-754	1.5	26
315	Expression of Programmed Death-Ligand 1 by Human Colonic CD90 Stromal Cells Differs Between Ulcerative Colitis and Crohn‚ Disease and Determines Their Capacity to Suppress Th1 Cells. *Frontiers in Immunology*, **2018**, 9, 1125	8.4	26
314	Use of thiopurines in inflammatory bowel disease. *World Journal of Gastroenterology*, **2013**, 19, 1040-8	5.6	26
313	Use of biological molecules in the treatment of inflammatory bowel disease. *Journal of Internal Medicine*, **2011**, 270, 15-28	10.8	26
312	Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. *Hepatology*, **2009**, 50, 653-4	11.2	26
311	The pH-sensing receptor OGR1 improves barrier function of epithelial cells and inhibits migration in an acidic environment. *American Journal of Physiology - Renal Physiology*, **2015**, 309, G475-90	5.1	25
310	Expression Patterns of TNF‚MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. *Journal of Crohn‚s and Colitis*, **2018**, 12, 347-354	1.5	25
309	The effects of vitamin A on cells of innate immunity in vitro. *Toxicology in Vitro*, **2013**, 27, 1525-32	3.6	25

308	Therapy of steroid-resistant inflammatory bowel disease. *Digestion*, **2012**, 86 Suppl 1, 11-5	3.6	25
307	Specific differences in migratory function of myofibroblasts isolated from Crohn's disease fistulae and strictures. *Inflammatory Bowel Diseases*, **2011**, 17, 202-12	4.5	25
306	Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. *Clinical and Experimental Immunology*, **2010**, 159, 87-92	6.2	25
305	Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. *Inflammatory Bowel Diseases*, **2010**, 16, 1505-13	4.5	25
304	Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. *PLoS ONE*, **2016**, 11, e0147682	3.7	25
303	Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening. *BMC Genomics*, **2016**, 17, 723	4.5	25
302	The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. *Journal of Crohn's and Colitis*, **2014**, 8, 1427-37	1.5	24
301	Anti-inflammatory Function of High-Density Lipoproteins via Autophagy of IκB Kinase. *Cellular and Molecular Gastroenterology and Hepatology*, **2015**, 1, 171-187.e1	7.9	24
300	Anemia in inflammatory bowel disease: an under-estimated problem?. *Frontiers in Medicine*, **2014**, 1, 58	4.9	24
299	Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease. *Digestion*, **2013**, 87, 212-21	3.6	24
298	High-density lipoprotein 3 retroendocytosis: a new lipoprotein pathway in the enterocyte (Caco-2). *Gastroenterology*, **1992**, 103, 469-80	13.3	24
297	Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2016**, 22, 2733-2747	4.5	24
296	Celiac disease diagnosis still significantly delayed - Doctor's but not patients' delay responsive for the increased total delay in women. *Digestive and Liver Disease*, **2016**, 48, 1148-54	3.3	23
295	Activation of protein tyrosine phosphatase non-receptor type 2 by spermidine exerts anti-inflammatory effects in human THP-1 monocytes and in a mouse model of acute colitis. *PLoS ONE*, **2013**, 8, e73703	3.7	23
294	Role of biological therapy for inflammatory bowel disease in developing countries. *Gut*, **2012**, 61, 706-12	19.2	23
293	Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey. *Inflammatory Bowel Diseases*, **2010**, 16, 933-8	4.5	23
292	Association of Alterations in Intestinal Microbiota With Impaired Psychological Function in Patients With Inflammatory Bowel Diseases in Remission. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2019-2029.e11	6.9	23
291	Hypoxia Positively Regulates the Expression of pH-Sensing G-Protein-Coupled Receptor OGR1 (GPR68). *Cellular and Molecular Gastroenterology and Hepatology*, **2016**, 2, 796-810	7.9	23

290	The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis. *Mucosal Immunology*, **2019**, 12, 733-745	9.2	23
289	The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients. *PLoS ONE*, **2018**, 13, e0199664	3.7	23
288	Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. *Journal of Lipid Research*, **2019**, 60, 1270-1283	6.3	22
287	Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. *Journal of Crohn's and Colitis*, **2019**, 13, 1292-1301	1.5	22
286	The role and advances of immunomodulator therapy for inflammatory bowel disease. *Expert Review of Gastroenterology and Hepatology*, **2015**, 9, 177-89	4.2	22
285	Bilberry-derived anthocyanins prevent IFN-γ-induced pro-inflammatory signalling and cytokine secretion in human THP-1 monocytic cells. *Digestion*, **2014**, 90, 179-89	3.6	22
284	Topical therapies in inflammatory bowel disease. *Digestion*, **2012**, 86 Suppl 1, 36-44	3.6	22
283	Clinical utility of anti-glycan antibodies in pediatric Crohn's disease in comparison with an adult cohort. *Inflammatory Bowel Diseases*, **2012**, 18, 1221-31	4.5	22
282	The role for dickkopf-homolog-1 in the pathogenesis of Crohn's disease-associated fistulae. *PLoS ONE*, **2013**, 8, e78882	3.7	22
281	Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn's disease (CD) mucosa. *International Journal of Colorectal Disease*, **2007**, 22, 611-23	3	22
280	Protein tyrosine phosphatase non-receptor type 2 and inflammatory bowel disease. *World Journal of Gastroenterology*, **2016**, 22, 1034-44	5.6	22
279	The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. *PLoS ONE*, **2016**, 11, e0155218	3.7	22
278	Efficacy of Endoscopic Dilation of Gastroduodenal Crohn's Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2514-2522.e8	6.9	21
277	Severe Sweet's Syndrome with Elevated Cutaneous Interleukin-1β after Azathioprine Exposure: Case Report and Review of the Literature. *Dermatology*, **2015**, 230, 293-8	4.4	21
276	Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course. *Journal of Crohn's and Colitis*, **2018**, 12, 1399-1409	1.5	21
275	Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond. *Cellular and Molecular Life Sciences*, **2013**, 70, 3391-404	10.3	21
274	Downregulation of duodenal SLC transporters and activation of proinflammatory signaling constitute the early response to high altitude in humans. *American Journal of Physiology - Renal Physiology*, **2014**, 307, G673-88	5.1	21
273	A new heterotopic transplant animal model of intestinal fibrosis. *Inflammatory Bowel Diseases*, **2013**, 19, 2302-14	4.5	21

272	Secretion of RANTES (CCL5) and interleukin-10 from mesenteric adipose tissue and from creeping fat in Crohn‚ disease: regulation by steroid treatment. *Journal of Gastroenterology and Hepatology (Australia)*, **2006**, 21, 1412-8	4	21
271	Glycoprotein (gp) 96 expression: induced during differentiation of intestinal macrophages but impaired in Crohn‚ disease. *Gut*, **2005**, 54, 935-43	19.2	21
270	Activation of pH-Sensing Receptor OGR1 (GPR68) Induces ER Stress Via the IRE1/JNK Pathway in an Intestinal Epithelial Cell Model. *Scientific Reports*, **2020**, 10, 1438	4.9	21
269	Role of protein tyrosine phosphatases in regulating the immune system: implications for chronic intestinal inflammation. *Inflammatory Bowel Diseases*, **2015**, 21, 645-55	4.5	20
268	Prdx6 Deficiency Ameliorates DSS Colitis: Relevance of Compensatory Antioxidant Mechanisms. *Journal of Crohn's and Colitis*, **2017**, 11, 871-884	1.5	20
267	Crohn‚ disease: loss of tolerance or a disorder of autophagy?. *Digestive Diseases*, **2014**, 32, 370-7	3.2	20
266	Microparticles and their impact on intestinal immunity. *Digestive Diseases*, **2012**, 30 Suppl 3, 47-54	3.2	20
265	Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. *Digestion*, **2013**, 88, 182-92	3.6	20
264	Efficacy and safety of certolizumab pegol in an unselected crohn‚ disease population: 26-week data of the FACTS II survey. *Inflammatory Bowel Diseases*, **2011**, 17, 1530-9	4.5	20
263	Decreased cytosolic glucocorticoid receptor levels in critically ill patients. *Anaesthesia and Intensive Care*, **2010**, 38, 133-40	1.1	20
262	Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn‚ disease. *International Journal of Colorectal Disease*, **2004**, 19, 319-24	3	20
261	Information Needs and Concerns of Patients with Inflammatory Bowel Disease: What Can We Learn from Participants in a Bilingual Clinical Cohort?. *PLoS ONE*, **2016**, 11, e0150620	3.7	20
260	Efficacy of JAK inhibitors in Crohn‚ Disease. *Journal of Crohn's and Colitis*, **2020**, 14, S746-S754	1.5	20
259	High Altitude Journeys, Flights and Hypoxia: Any Role for Disease Flares in IBD Patients?. *Digestive Diseases*, **2016**, 34, 78-83	3.2	20
258	Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn‚ Disease. *Inflammatory Bowel Diseases*, **2016**, 22, 2648-2657	4.5	20
257	Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. *Gastroenterology*, **2021**, 161, 1118-1132	13.3	20
256	Clinical Utility of Biomarkers in IBD. *Current Gastroenterology Reports*, **2015**, 17, 26	5	19
255	The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort. *Inflammatory Bowel Diseases*, **2018**, 24, 1768-1779	4.5	19

254	Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. *European Journal of Gastroenterology and Hepatology*, **2018**, 30, 612-620	2.2	19
253	Effects of oral antibiotics and isotretinoin on the murine gut microbiota. *International Journal of Antimicrobial Agents*, **2017**, 50, 342-351	14.3	19
252	Monitoring disease activity and progression in Crohn's disease. A Swiss perspective on the IBD ahead "optimised monitoring" recommendations. *Digestion*, **2014**, 89, 299-309	3.6	19
251	Beta-glucosidase 2 knockout mice with increased glucosylceramide show impaired liver regeneration. *Liver International*, **2012**, 32, 1354-62	7.9	19
250	Heat waves, incidence of infectious gastroenteritis, and relapse rates of inflammatory bowel disease: a retrospective controlled observational study. *American Journal of Gastroenterology*, **2013** , 108, 1480-5	0.7	19
249	Physiological role of macrophage inflammatory protein-3 alpha induction during maturation of intestinal macrophages. *Journal of Immunology*, **2005**, 175, 1389-98	5.3	19
248	Long noncoding RNA H19X is a key mediator of TGF-β-driven fibrosis. *Journal of Clinical Investigation*, **2020**, 130, 4888-4905	15.9	19
247	New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways. *Swiss Medical Weekly*, **2018**, 148, w14599	3.1	19
246	Lack of the pH-sensing Receptor TDAG8 [GPR65] in Macrophages Plays a Detrimental Role in Murine Models of Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2019**, 13, 245-258	1.5	19
245	Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study. *American Journal of Gastroenterology*, **2019**, 114, 116-126	0.7	19
244	Prediction of low bone mineral density in patients with inflammatory bowel diseases. *United European Gastroenterology Journal*, **2016**, 4, 669-676	5.3	18
243	Fistulizing Crohn's Disease. *Clinical and Translational Gastroenterology*, **2017**, 8, e106	4.2	18
242	Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. *Medicine (United States)*, **2017**, 96, e6788	1.8	18
241	Factors Promoting Development of Fibrosis in Crohn's Disease. *Frontiers in Medicine*, **2017**, 4, 96	4.9	18
240	Transcriptional analysis of left-sided colitis, pancolitis, and ulcerative colitis-associated dysplasia. *Inflammatory Bowel Diseases*, **2014**, 20, 2340-52	4.5	18
239	A role for tumor necrosis factor and bacterial antigens in the pathogenesis of Crohn's disease-associated fistulae. *Inflammatory Bowel Diseases*, **2013**, 19, 2878-87	4.5	18
238	Collagen XVI induces formation of focal contacts on intestinal myofibroblasts isolated from the normal and inflamed intestinal tract. *Matrix Biology*, **2010**, 29, 177-93	11.4	18
237	Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. *Digestion*, **2010**, 81, 78-85	3.6	18

236	Multiparameter immunofluorescence on paraffin-embedded tissue sections. *Applied Immunohistochemistry and Molecular Morphology*, **2006**, 14, 225-8	1.9	18
235	Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-catenin. *Laboratory Investigation*, **2005**, 85, 124-36	5.9	18
234	Systematic Analysis of the Impact of Diagnostic Delay on Bowel Damage in Paediatric Versus Adult Onset Crohn‚ Disease. *Journal of Crohn‚s and Colitis*, **2019**, 13, 1334-1342	1.5	17
233	Cogan‚ Syndrome in Patients With Inflammatory Bowel Disease--A Case Series. *Journal of Crohn‚s and Colitis*, **2015**, 9, 886-90	1.5	17
232	Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. *Gastroenterology*, **2019**,	13.3	17
231	Induction or exacerbation of psoriasis in patients with Crohn‚ disease under treatment with anti-TNF antibodies. *Digestion*, **2014**, 89, 209-15	3.6	17
230	Association between Cogan‚ syndrome and inflammatory bowel disease: a case series. *Journal of Crohn‚s and Colitis*, **2011**, 5, 64-8	1.5	17
229	Microbial sensing by the intestinal epithelium in the pathogenesis of inflammatory bowel disease. *International Journal of Inflammation*, **2010**, 2010, 671258	6.4	17
228	Downregulation of the ubiquitin-proteasome system in normal colonic macrophages and reinduction in inflammatory bowel disease. *Digestion*, **2012**, 86, 34-47	3.6	17
227	The role of domestic hygiene in inflammatory bowel diseases: hepatitis A and worm infestations. *European Journal of Gastroenterology and Hepatology*, **2008**, 20, 561-6	2.2	17
226	Review: new anti-cytokines for IBD: what is in the pipeline?. *Current Drug Targets*, **2013**, 14, 1405-20	3	17
225	Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). *International Journal of Epidemiology*, **2019**, 48, 385-386f	7.8	16
224	The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation. *BMC Gastroenterology*, **2019**, 19, 2	3	16
223	Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 540-8	6.1	16
222	Species-specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn‚ associated NOD2 gene variants. *Clinical and Experimental Immunology*, **2015**, 179, 426-34	6.2	16
221	Pregnancy and breastfeeding in inflammatory bowel disease. *Digestion*, **2012**, 86 Suppl 1, 45-54	3.6	16
220	Intestinal absorption and vitamin levels: is a new focus needed?. *Digestive Diseases*, **2012**, 30 Suppl 3, 73-80	3.2	16
219	Interaction between susceptibility and environment: examples from the digestive tract. *Digestive Diseases*, **2011**, 29, 136-43	3.2	16

218	Fistula treatment: The unresolved challenge. *Digestive Diseases*, **2010**, 28, 556-64	3.2	16
217	A case of recurrent gastrointestinal bleeding and protein-losing gastroenteropathy. *Nature Reviews Gastroenterology & Hepatology*, **2007**, 4, 288-93		16
216	Possible Adverse Effects of Food Additive E171 (Titanium Dioxide) Related to Particle Specific Human Toxicity, Including the Immune System. *International Journal of Molecular Sciences*, **2020**, 22,	6.3	16
215	Cell-specific Activation of the Nrf2 Antioxidant Pathway Increases Mucosal Inflammation in Acute but Not in Chronic Colitis. *Journal of Crohn's and Colitis*, **2017**, 11, 485-499	1.5	16
214	Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. *PLoS ONE*, **2019**, 14, e0210436	3.7	15
213	Vaccination in Patients with Inflammatory Bowel Diseases. *Digestion*, **2020**, 101 Suppl 1, 58-68	3.6	15
212	The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives. *Inflammatory Intestinal Diseases*, **2018**, 2, 189-199	2.5	15
211	Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease?. *European Journal of Gastroenterology and Hepatology*, **2017**, 29, 322-330	2.2	15
210	Hemoglobin and hematocrit levels in the prediction of complicated Crohn's disease behavior--a cohort study. *PLoS ONE*, **2014**, 9, e104706	3.7	15
209	Mucosal healing with anti-TNF antibodies. *Digestion*, **2012**, 86 Suppl 1, 16-22	3.6	15
208	Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF). *International Journal of Colorectal Disease*, **2008**, 23, 947-55	3	15
207	Glucocorticoid receptor isoform expression does not predict steroid treatment response in IBD. *Gut*, **2007**, 56, 1328-9	19.2	15
206	Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn's disease. *European Journal of Gastroenterology and Hepatology*, **2001**, 13, 1431-7	2.2	15
205	Frequency and nature of incidental extra-enteric lesions found on magnetic resonance enterography (MR-E) in patients with inflammatory bowel diseases (IBD). *PLoS ONE*, **2009**, 4, e4863	3.7	15
204	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. *Gastroenterology*, **2021**, 160, 1452-1460.e21	13.3	15
203	β integrin serves as a novel serum tumor marker for colorectal carcinoma. *International Journal of Cancer*, **2019**, 145, 678-685	7.5	15
202	Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression. *Clinical and Experimental Immunology*, **2015**, 181, 343-56	6.2	14
201	Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. *Maturitas*, **2018**, 110, 71-78	5	14

200	Medical management of ulcerative colitis. *Digestive Diseases*, **2009**, 27, 542-9	3.2	14
199	Gene expression profiles of mucosal fibroblasts from strictured and nonstrictured areas of patients with Crohn's disease. *Inflammatory Bowel Diseases*, **2009**, 15, 212-23	4.5	14
198	NOD2/CARD15 polymorphisms in allogeneic stem-cell transplantation from unrelated donors: T depletion matters. *Journal of Clinical Oncology*, **2008**, 26, 338-9; author reply 339	2.2	14
197	Influence of cholesterol supply on cell growth and differentiation in cultured enterocytes (CaCo-2). *Digestion*, **1995**, 56, 57-66	3.6	14
196	Intestinal Activation of pH-Sensing Receptor OGR1 [GPR68] Contributes to Fibrogenesis. *Journal of Crohn's and Colitis*, **2018**, 12, 1348-1358	1.5	14
195	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. *EClinicalMedicine*, **2020**, 20, 100271	11.3	13
194	Treatment Algorithms for Crohn's Disease. *Digestion*, **2020**, 101 Suppl 1, 43-57	3.6	13
193	Doxycycline, metronidazole and isotretinoin: Do they modify microRNA/mRNA expression profiles and function in murine T-cells?. *Scientific Reports*, **2016**, 6, 37082	4.9	13
192	Sphingomyelin and phosphatidylcholine contrarily affect the induction of apoptosis in intestinal epithelial cells. *Molecular Nutrition and Food Research*, **2014**, 58, 782-98	5.9	13
191	Coping is excellent in Swiss Children with inflammatory bowel disease: results from the Swiss IBD cohort study. *Journal of Crohn's and Colitis*, **2014**, 8, 409-20	1.5	13
190	The importance of gut microbiota in mediating the effect of NOD2 defects in inflammatory bowel disease. *Gut*, **2010**, 59, 153-4	19.2	13
189	Treatment of severe ulcerative colitis: differences in elderly patients?. *Digestive Diseases*, **2009**, 27, 315-21	3.2	13
188	The effects of NOD2/CARD15 mutations on the function of the intestinal barrier. *Journal of Crohn's and Colitis*, **2007**, 1, 53-60	1.5	13
187	Systematic Evaluation of Diagnostic Delay in Pediatric Inflammatory Bowel Disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2017**, 64, 245-247	2.8	12
186	Patients' information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients. *Scandinavian Journal of Gastroenterology*, **2014**, 49, 662-73	2.4	12
185	Crohn's disease of the esophagus: treatment of an esophagobronchial fistula with the novel liquid embolic polymer "onyx". *Zeitschrift Fur Gastroenterologie*, **2006**, 44, 599-602	1.6	12
184	Vascular endothelial growth factor secretion from mesenteric adipose tissue and from creeping fat in Crohn's disease. *Journal of Gastroenterology and Hepatology (Australia)*, **2006**, 21, 1419-23	4	12
183	Coombs-positive autoimmune hemolytic anemia in Crohn's disease. *European Journal of Gastroenterology and Hepatology*, **2005**, 17, 661-6	2.2	12

182	Significance of anti-inflammatory effects of PPARgamma agonists?. *Gut*, **2006**, 55, 1067-9	19.2	12
181	Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis. *Journal of Crohn's and Colitis*, **2019**, 13, 785-797	1.5	12
180	The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series. *Inflammatory Intestinal Diseases*, **2017**, 2, 131-138	2.5	11
179	A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis. *Inflammatory Intestinal Diseases*, **2020**, 5, 180-190	2.5	11
178	Management of the Elderly Inflammatory Bowel Disease Patient. *Digestion*, **2020**, 101 Suppl 1, 105-119	3.6	11
177	The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease. *United European Gastroenterology Journal*, **2016**, 4, 506-14	5.3	11
176	Afferent nerve sensitivity is decreased by an iNOS-dependent mechanism during indomethacin-induced inflammation in the murine jejunum in vitro. *Neurogastroenterology and Motility*, **2009**, 21, 322-34	4	11
175	Differential afferent sensitivity to mucosal lipopolysaccharide from Salmonella typhimurium and Escherichia coli in the rat jejunum. *Neurogastroenterology and Motility*, **2009**, 21, 1335-e129	4	11
174	A new organotypic model to study cell interactions in the intestinal mucosa. *European Journal of Gastroenterology and Hepatology*, **2006**, 18, 901-9	2.2	11
173	Regulation of cholesterol metabolism and low-density lipoprotein binding in human intestinal Caco-2 cells. *Digestion*, **1992**, 51, 10-7	3.6	11
172	HDL3-retroendocytosis in cultured small intestinal crypt cells: a novel mechanism of cholesterol efflux. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1991**, 1095, 30-8	4.9	11
171	Role of soluble factors and three-dimensional culture in in vitro differentiation of intestinal macrophages. *World Journal of Gastroenterology*, **2007**, 13, 1032-41	5.6	11
170	Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. *Digestive Diseases*, **2018**, 36, 123-129	3.2	11
169	Clinicopathological and Molecular Specificities of Inflammatory Bowel Disease-Related Colorectal Neoplastic Lesions: The Role of Inflammation. *Journal of Crohn's and Colitis*, **2018**, 12, 1486-1498	1.5	11
168	Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. *Therapeutic Advances in Gastroenterology*, **2019**, 12, 1756284819865142	4.7	10
167	Preventive Trichuris suis ova (TSO) treatment protects immunocompetent rabbits from DSS colitis but may be detrimental under conditions of immunosuppression. *Scientific Reports*, **2017**, 7, 16500	4.9	10
166	Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey. *Nutrition Journal*, **2015**, 14, 78	4.3	10
165	Lack of transketolase-like (TKTL) 1 aggravates murine experimental colitis. *American Journal of Physiology - Renal Physiology*, **2011**, 300, G598-607	5.1	10

164	Immune-non immune networks in intestinal inflammation. *Current Drug Targets*, **2008**, 9, 388-94	3	10
163	BCL2 Regulates Differentiation of Intestinal Fibroblasts. *Inflammatory Bowel Diseases*, **2018**, 24, 1953-1966	4.5	10
162	Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis. *Mucosal Immunology*, **2019**, 12, 1336-1347	9.2	9
161	Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing. *Digestion*, **2016**, 93, 249-59	3.6	9
160	The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation. *Annals of the New York Academy of Sciences*, **2012**, 1257, 93-102	6.5	9
159	Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. *Inflammatory Bowel Diseases*, **2015**, 21, 1348-58	4.5	9
158	New therapeutic avenues for treatment of fibrosis: can we learn from other diseases?. *Digestive Diseases*, **2014**, 32 Suppl 1, 39-49	3.2	9
157	Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. *Alimentary Pharmacology and Therapeutics*, **2010**, 32, 1007-16	6.1	9
156	Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. *European Journal of Gastroenterology and Hepatology*, **2010**, 22, 1352-7	2.2	9
155	(GT)N dinucleotide repeat polymorphism of haem oxygenase-1 promotor region is not associated with inflammatory bowel disease risk or disease course. *Clinical and Experimental Immunology*, **2008** , 153, 81-5	6.2	9
154	HDL3-mediated cholesterol efflux from cultured enterocytes: the role of apoproteins A-I and A-II. *Lipids*, **1994**, 29, 735-45	1.6	9
153	Risk factors for complications in patients with ulcerative colitis. *United European Gastroenterology Journal*, **2016**, 4, 281-7	5.3	9
152	The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. *Digestion*, **2016**, 93, 182-92	3.6	9
151	Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas. *Journal of Crohn's and Colitis*, **2019**, 13, 798-806	1.5	9
150	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. *Cell Host and Microbe*, **2021**, 29, 1573-1588.e7	23.4	9
149	Iron Prevents Hypoxia-Associated Inflammation Through the Regulation of Nuclear Factor-B in the Intestinal Epithelium. *Cellular and Molecular Gastroenterology and Hepatology*, **2019**, 7, 339-355	7.9	8
148	The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. *PLoS ONE*, **2019**, 14, e0211554	3.7	8
147	Oral administration of dextran sodium sulphate induces a caecum-localized colitis in rabbits. *International Journal of Experimental Pathology*, **2015**, 96, 151-62	2.8	8

146	Donor Nucleotide-Binding Oligomerization-Containing Protein 2 (NOD2) Single Nucleotide Polymorphism 13 Is Associated with Septic Shock after Allogeneic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1399-404	4.7	8
145	Alicaforsen in the treatment of pouchitis. *Immunotherapy*, **2017**, 9, 1143-1152	3.8	8
144	Cell-wall deficient L. monocytogenes L-forms feature abrogated pathogenicity. *Frontiers in Cellular and Infection Microbiology*, **2014**, 4, 60	5.9	8
143	Effects of retinoids in mouse models of colitis: benefit or danger to the gastrointestinal tract?. *Inflammatory Bowel Diseases*, **2013**, 19, 2356-65	4.5	8
142	A shift from oral to intravenous iron supplementation therapy is observed over time in a large swiss cohort of patients with inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2013**, 19, 840-6	4.5	8
141	Lessons from a transplant patient with diarrhea, cryptosporidial infection, and possible mycophenolate mofetil-associated colitis. *Transplant Infectious Disease*, **2011**, 13, 416-8	2.7	8
140	NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. *Zeitschrift Fur Gastroenterologie*, **2008**, 46, 259-65	1.6	8
139	Mevalonate is essential for growth of porcine and human vascular smooth muscle cells in vitro. *Basic Research in Cardiology*, **1995**, 90, 443-50	11.8	8
138	Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner. *Journal of Clinical Investigation*, **2019**, 129, 2527-2541	15.9	8
137	Regulation of the expression of chaperone gp96 in macrophages and dendritic cells. *PLoS ONE*, **2013**, 8, e76350	3.7	8
136	Targeting the RAS pathway by mitogen-activated protein kinase inhibitors. *Swiss Medical Weekly*, **2015**, 145, w14207	3.1	8
135	The Innate Immune System: A Trigger for Many Chronic Inflammatory Intestinal Diseases. *Inflammatory Intestinal Diseases*, **2016**, 1, 70-77	2.5	8
134	Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus. *Digestion*, **2020**, 101, 683-691	3.6	8
133	Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. *Inflammatory Bowel Diseases*, **2021**, 27, 816-825	4.5	8
132	The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding. *United European Gastroenterology Journal*, **2018**, 6, 1007-1014	5.3	8
131	Helminth therapy for organic diseases?. *Translational Research*, **2015**, 166, 586-601	11	7
130	Assessment of inflammatory bowel disease patientß needs and problems from a nursing perspective. *Digestion*, **2015**, 91, 128-41	3.6	7
129	Rapid expansion of Treg cells protects from collateral colitis following a viral trigger. *Nature Communications*, **2020**, 11, 1522	17.4	7

128	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. *BMJ Open Gastroenterology*, **2016**, 3, e000092	3.9	7
127	Steroid use in Crohn's disease. *Drugs*, **2014**, 74, 313-24	12.1	7
126	Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease. *Inflammatory Bowel Diseases*, **2013**, 19, E4-6	4.5	7
125	Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. *Scandinavian Journal of Gastroenterology*, **2014**, 49, 1207-18	2.4	7
124	Knock-out of β-glucosidase 2 has no influence on dextran sulfate sodium-induced colitis. *Digestion*, **2011**, 84, 156-67	3.6	7
123	Environmental factors and their impact on the intestinal microbiota: a role for human disease?. *Digestive Diseases*, **2012**, 30 Suppl 3, 20-7	3.2	7
122	(E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa. *International Journal of Colorectal Disease*, **2007**, 22, 303-12	3	7
121	Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer. *International Journal of Colorectal Disease*, **2006**, 21, 573-81	3	7
120	Can NOD2/CARD15 mutations predict intestinal graft-versus-host disease and aid our understanding of Crohn's disease?. *Nature Reviews Gastroenterology & Hepatology*, **2004**, 1, 62-3		7
119	Interferon gamma downregulates IL-8 production in primary human colonic epithelial cells without induction of apoptosis. *International Journal of Colorectal Disease*, **2004**, 19, 421-9	3	7
118	Improved separation of radioactively labelled cellular phospholipids by high-performance liquid chromatography. *Biomedical Applications*, **1994**, 656, 73-6		7
117	Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. *United European Gastroenterology Journal*, **2020** , 8, 1196-1207	5.3	7
116	Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. *PLoS ONE*, **2016**, 11, e0160215	3.7	7
115	Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study. *BMJ Open*, **2017**, 7, e013477	3	6
114	Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2050-2059.e1	6.9	6
113	Gp96 deficiency affects TLR4 functionality and impairs ERK and p38 phosphorylation. *PLoS ONE*, **2018**, 13, e0193003	3.7	6
112	VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study. *BMJ Open*, **2015**, 5, e007306	3	6
111	Primary human colonic epithelial cells are transiently protected from anoikis by a Src-dependent mechanism. *Biochemical and Biophysical Research Communications*, **2009**, 390, 908-14	3.4	6

110	Morphology of CaCo-2 cells varies in different cell batches. *In Vitro Cellular and Developmental Biology - Animal*, **1994**, 30A, 289-91	2.6	6
109	Fatigue in inflammatory bowel disease and its impact on daily activities. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 138-149	6.1	6
108	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. *Inflammatory Intestinal Diseases*, **2020**, 5, 109-116	2.5	6
107	Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. *Inflammatory Intestinal Diseases*, **2017**, 1, 172-181	2.5	6
106	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. *Inflammatory Bowel Diseases*, **2021**, 27, 106-122	4.5	6
105	Nutritional Lipids and Mucosal Inflammation. *Molecular Nutrition and Food Research*, **2021**, 65, e1901269	5.9	6
104	Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients. *Journal of Clinical Gastroenterology*, **2018**, 52, 25-29	3	6
103	Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer. *Strahlentherapie Und Onkologie*, **2020**, 196, 356-367	4.3	5
102	Rectal Insulin Instillation Inhibits Inflammation and Tumor Development in Chemically Induced Colitis. *Journal of Crohn's and Colitis*, **2018**, 12, 1459-1474	1.5	5
101	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®) for active, mild-to-moderate ulcerative colitis. *United European Gastroenterology Journal*, **2019**, 7, 1171-1182	5.3	5
100	Volcano-like intermittent bleeding activity for seven years from an arterio-enteric fistula on a kidney graft site after pancreas-kidney transplantation: a case report. *Journal of Medical Case Reports*, **2010**, 4, 357	1.2	5
99	Dying in yoghurt: the number of living bacteria in probiotic yoghurt decreases under exposure to room temperature. *Digestion*, **2011**, 83, 13-7	3.6	5
98	Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients. *Cancer Immunology, Immunotherapy*, **2006**, 55, 528-37	7.4	5
97	Sonographische Kontrolle von Magensonden bei Intensivpatienten. *Intensivmedizin Und Notfallmedizin*, **2003**, 40, 693-697		5
96	Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. *Inflammatory Intestinal Diseases*, **2021**, 6, 38-47	2.5	5
95	Reconsidering the "protective" hypothesis of Helicobacter pylori infection in eosinophilic esophagitis. *Annals of the New York Academy of Sciences*, **2020**, 1481, 59-71	6.5	5
94	Contribution of CD3+CD8- and CD3+CD8+ T Cells to TNF-α Overexpression in Crohn Disease-Associated Perianal Fistulas and Induction of Epithelial-Mesenchymal Transition in HT-29 Cells. *Inflammatory Bowel Diseases*, **2021**, 27, 538-549	4.5	5
93	Dysbiotic microbiota interactions in Crohn's disease. *Gut Microbes*, **2021**, 13, 1949096	8.8	5

92	Systemic Jak1 activation provokes hepatic inflammation and imbalanced FGF23 production and cleavage. *FASEB Journal*, **2021**, 35, e21302	0.9	5
91	Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-Therapy: Pathophysiology and Clinical Implications. *Digestive Diseases*, **2017**, 35, 5-12	3.2	4
90	The Impact of Cold Spells on the Incidence of Infectious Gastroenteritis and Relapse Rates of Inflammatory Bowel Disease: A Retrospective Controlled Observational Study. *Inflammatory Intestinal Diseases*, **2017**, 2, 124-130	2.5	4
89	New Onset, Aggravation and Recurrence of Crohn's Disease upon Treatment with Three Different Tumor Necrosis Factor Inhibitors. *Case Reports in Gastroenterology*, **2015**, 9, 106-12	1	4
88	The history and philosophy of inflammatory bowel disease. *Digestive Diseases*, **2013**, 31, 270-7	3.2	4
87	Impaired removal of V'(+) lymphocytes aggravates colitis in mice deficient for B cell lymphoma-2-interacting mediator of cell death (Bim). *Clinical and Experimental Immunology*, **2013**, 173, 493-501	6.2	4
86	Intracellular transport of high-density lipoprotein 3 in intestinal epithelial cells (Caco-2) is tubulin associated. *Digestion*, **2000**, 61, 47-58	3.6	4
85	Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. *Therapeutic Advances in Gastroenterology*, **2020**, 13, 1756284820959252	4.7	4
84	Feasibility of an 8-item questionnaire for early diagnosis of inflammatory bowel disease in primary care. *Journal of Evaluation in Clinical Practice*, **2019**, 25, 155-162	2.5	4
83	Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development. *Journal of Clinical Investigation*, **2021**, 131,	15.9	4
82	Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease. *PLoS ONE*, **2018**, 13, e0194222	3.7	3
81	Addressing current treatment challenges in Crohn's disease in real life: a physician's survey. *Digestive and Liver Disease*, **2014**, 46, 1066-71	3.3	3
80	Gastroresistant oral peptide for fluorescence imaging of colonic inflammation. *Journal of Controlled Release*, **2017**, 262, 118-126	11.7	3
79	Prevalence and Determinants of Job Stress in Patients with Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2017**, 23, 310-317	4.5	3
78	Integrating Imaging into Clinical Practice in Inflammatory Bowel Disease. *Digestive Diseases*, **2015**, 33 Suppl 1, 37-43	3.2	3
77	MIP-3 expression in macrophages is NOD dependent. *Digestion*, **2012**, 85, 192-201	3.6	3
76	Treatment algorithm for moderate to severe ulcerative colitis. *Swiss Medical Weekly*, **2011**, 141, w13235	3.1	3
75	Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance. *Frontiers in Immunology*, **2020**, 11, 1856	8.4	3

74	Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 53-67	6.1	3
73	Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2021**,	4.5	3
72	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. *Inflammatory Bowel Diseases*, **2019**, 25, 1357-1366	4.5	3
71	Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study. *PLoS ONE*, **2019**, 14, e0215738	3.7	2
70	The Influence of Breastfeeding, Cesarean Section, Pet Animals, and Urbanization on the Development of Inflammatory Bowel Disease: Data from the Swiss IBD Cohort Study. *Inflammatory Intestinal Diseases*, **2020**, 5, 170-179	2.5	2
69	Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. *Journal of Crohn's and Colitis*, **2017**, 11, 256-257	1.5	2
68	Su1261 Expression of Interleukins 22 and 33, Matrix Metalloproteinases 9 and 13, Mast Cell Markers and Hypoxia-Inducible Factor 1 in Crohn's Disease Associated Fistulae. *Gastroenterology*, **2013**, 144, S-441-S-442	13.3	2
67	A distinct pattern of disease-associated single nucleotide polymorphisms in IBD risk genes in a family with Crohn's disease. *European Journal of Gastroenterology and Hepatology*, **2014**, 26, 803-6	2.2	2
66	Topische Therapie bei chronisch-entzündlichen Darmerkrankungen. *Coloproctology*, **2014**, 36, 353-358	0.2	2
65	Treatment of pouchitis with dehydroepiandrosterone (DHEA) - a case report. *Zeitschrift Fur Gastroenterologie*, **2003**, 41, 1087-90	1.6	2
64	Late onset primary oxalosis type I: an uncommon presentation of a rare disease. *European Journal of Gastroenterology and Hepatology*, **1998**, 10, 809-12	2.2	2
63	Ingested nano- and microsized polystyrene particles surpass the intestinal barrier and accumulate in the body.. *NanoImpact*, **2022**, 25, 100374	5.6	2
62	Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. *Digestive Diseases and Sciences*, **2020**, 65, 2654-2663	4	2
61	Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn's disease: A case series. *Colorectal Disease*, **2021**, 23, 1444-1450	2.1	2
60	New Therapeutic Approach for Intestinal Fibrosis Through Inhibition of pH-Sensing Receptor GPR4. *Inflammatory Bowel Diseases*, **2021**,	4.5	2
59	Novel Strategies to Prevent Total Parenteral Nutrition-Induced Gut and Liver Inflammation, and Adverse Metabolic Outcomes. *Molecular Nutrition and Food Research*, **2021**, 65, e1901270	5.9	2
58	Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211033763	4.7	2
57	Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management. *BMC Gastroenterology*, **2021**, 21, 53	3	2

56	Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach. *Gastrointestinal Endoscopy*, **2021**, 94, 379-390.e7	5.2	2
55	The Intestinal Barrier-Shielding the Body from Nano- and Microparticles in Our Diet.. *Metabolites*, **2022**, 12,	5.6	2
54	The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity. *Digestive and Liver Disease*, **2017**, 49, 268-272	3.3	1
53	Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study. *Therapeutic Advances in Gastroenterology*, **2020**, 13, 1756284819895217	4.7	1
52	Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells. *Inflammatory Intestinal Diseases*, **2018**, 2, 211-218	2.5	1
51	CrohnÞ disease: Fistulising disease--a problem shared is a problem halved?. *Nature Reviews Gastroenterology and Hepatology*, **2014**, 11, 581-3	24.2	1
50	Exogenous heat shock protein gp96 ameliorates CD4+CD62L+ T-cell-mediated transfer colitis. *Inflammatory Bowel Diseases*, **2014**, 20, 1933-41	4.5	1
49	Topische Therapie bei chronisch-entzÕndlichen Darmerkrankungen. *Gastroenterologe*, **2013**, 8, 197-204	0.1	1
48	Mast cells and the cyclooxygenase pathway mediate colonic afferent nerve sensitization in a murine colitis model. *Autonomic Neuroscience: Basic and Clinical*, **2013**, 174, 47-53	2.4	1
47	Recognition of commensal microbes: if innate responses are NOD in balance. *Expert Review of Clinical Immunology*, **2010**, 6, 205-10	5.1	1
46	Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.. *Therapeutic Advances in Gastroenterology*, **2022**, 15, 17562848221074188	4.7	1
45	Inflammatory Bowel Disease in Travelers. *Gastroenterology and Hepatology*, **2018**, 14, 377-379	0.7	1
44	The Role of the Chaperone Grp94/Gp96 in the Intestinal Barrier and Innate Immune Functions. *Current Immunology Reviews*, **2017**, 13,	1.3	1
43	Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2456-2462	6.9	1
42	A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. *British Journal of Pharmacology*, **2021**, 178, 3157-3175	8.6	1
41	Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. *Inflammatory Bowel Diseases*, **2021**, 27, 1986-1998	4.5	1
40	Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N in Dendritic Cells to Protect from Elevated Colitis. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
39	Can the CalproQuest predict a positive Calprotectin test? A prospective diagnostic study. *PLoS ONE* , **2019**, 14, e0224961	3.7	1

38	Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. *Journal of Crohn's and Colitis*, **2020**,	1.5	1
37	Choice of Lipid Emulsion Determines Inflammation of the Gut-Liver Axis, Incretin Profile, and Insulin Signaling in a Murine Model of Total Parenteral Nutrition. *Molecular Nutrition and Food Research*, **2021**, 65, e2000412	5.9	1
36	A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis. *Inflammatory Intestinal Diseases*, **2021**, 6, 140-153	2.5	1
35	Perianal fistulodesis - A pilot study of a novel minimally invasive surgical and medical approach for closure of perianal fistulae. *World Journal of Gastrointestinal Surgery*, **2021**, 13, 187-197	2.4	1
34	Diet and Inflammatory Bowel Disease: What Quality Standards Should Be Applied in Clinical and Laboratory Studies?. *Molecular Nutrition and Food Research*, **2021**, 65, e2000514	5.9	1
33	The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients. *United European Gastroenterology Journal*, **2021**, 9, 773	5.3	1
32	Anthocyanins and anthocyanidins are poor inhibitors of CYP2D6. *Methods and Findings in Experimental and Clinical Pharmacology*, **2009**, 31, 3-9		1
31	Immune Cells: Monocytes and Macrophages **2017**, 119-122		0
30	Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patients. *Therapeutic Advances in Gastroenterology*, **2018**, 11, 1756283X18757715	4.7	0
29	Gastrointestinale Infektionen. *Gastroenterologe*, **2014**, 9, 340-341	0.1	0
28	Medikamentöse Therapie der Colitis ulcerosa und Pouchitis **2020**, 285-303		0
27	MMP9 expression in intestinal fistula from patients with fistulizing CD and from human xenograft mouse model. *Tissue Barriers*, **2021**, 1994350	4.3	0
26	Inflammatory bowel disease in sub-Saharan Africa: a protocol of a prospective registry with a nested case-control study. *BMJ Open*, **2020**, 10, e039456	3	0
25	Responses to the Letter to the Editor by Brusciano et al. *Neurogastroenterology and Motility*, **2020**, 32, e13981	4	0
24	Clostridium-difficile-Infektion. *Gastroenterologe*, **2017**, 12, 237-252	0.1	
23	Anthocyane, Heidelbeeren und Curcuma: Wirksame Therapeutika bei Darmentzündungen?. *Schweizerische Zeitschrift Für GanzheitsMedizin*, **2017**, 29, 137-140		
22	Large-Scale Integrative Analysis of Epigenetic Modifications Induced by Isotretinoin, Doxycycline and Metronidazole in Murine Colonic Intestinal Epithelial Cells. *Epigenomes*, **2017**, 1, 24	2.3	
21	Recurrent Fever and Failure to Thrive in an 11-Year-Old Boy. *Case Reports in Gastroenterology*, **2019**, 13, 350-356	1	

20	Serum REG3alpha and C-Reactive Protein Levels in Crohn's Disease Patients Undergoing Immunoablation and Autologous Hemopoetic Stem Cell Transplantation in the ASTIC Trial. *Digestion*, **2015**, 92, 83-9	3.6
19	Is inflammatory bowel disease more severe when it appears at younger ages?. *Digestion*, **2010**, 81, 235-6	3.6
18	Intensified Anti-TNF-Alpha Therapy and Bacterial-DNA Translocation in Patients With Mutated NOD2/ATG16L1-Combined Genotypes. *Inflammatory Bowel Diseases*, **2012**, 18, S60	4.5
17	Kurzdarstellung der Therapieleitlinien zur Colitis ulcerosa. *Viszeralmedizin*, **2009**, 25, 187-192	
16	Chronisch-entzündliche Darmerkrankungen - Konservative und postoperative Therapie. *Viszeralchirurgie*, **2007**, 42, 359-365	
15	Genomics and inductive reasoning: revolution, renaissance, or rhetoric?. *Genetics in Medicine*, **2003**, 5, 476-8	8.1
14	Multi-site therapeutic modalities for inflammatory bowel diseases: mechanisms of action **2003**, 523-551	
13	A janus-headed polyp: adenoma and carcinoma with a single stalk. *Endoscopy*, **2005**, 37, 96	3.4
12	Klassifikationen, Indizes, Aktivitätsbeurteilung **2020**, 117-136	
11	Klinik der Colitis ulcerosa und Pouchitis **2020**, 87-94	
10	Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. *BMC Gastroenterology*, **2021**, 21, 310	3
9	Multi-site therapeutic modalities for inflammatory bowel diseases: mechanisms of action **2003**, 523-551	
8	NOD2/CARD15 Mutations Associate with Transplant Related Mortality and GvHD in HLA-Identical Sibling Transplants: Detailed Analysis of Single SNPs in 211 Recipient/Donor Pairs.. *Blood*, **2004**, 104, 424-424	2.2
7	NOD2/CARD15 Variants of Donor and Recipient as Critical Risk Factors for the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Stem Cell Transplantation.. *Blood*, **2005**, 106, 144-144	2.2
6	Polymorphisms within epithelial receptors: NOD2/CARD15. *Methods in Molecular Medicine*, **2007**, 134, 115-22	
5	Interleukin 10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. *FASEB Journal*, **2007**, 21, A589	0.9
4	The Defect in HDL3 Mediated Efflux of Newly Synthesized Cholesterol is Associated with Impaired Activation of Protein Kinase C in Tangier Fibroblasts **1995**, 79-87	
3	Eine neue Dynamik in den Therapiestrategien der chronisch-entzündlichen Darmerkrankungen. *Gastroenterologe*, **2019**, 14, 413-414	0.1

2	Hypoxia Reduces the Transcription of Fibrotic Markers in the Intestinal Mucosa. *Inflammatory Intestinal Diseases*, **2021**, 6, 87-100	2.5
1	Challenges of Translation of Anti-Fibrotic Therapies into Clinical Practice in IBD **2018**, 295-305	